T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

NCT02133196 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

85

Enrollment

NIH

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Advanced NSCLC
Adenosquamous Carcinoma
Adenocarcinoma

Interventions

DRUG: Aldesleukin
DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: Young TIL

Sponsor

National Cancer Institute (NCI)